Articles médicaux

Year Title Authors Topic Reference Journal
2023 Adjuvant Endocrine Therapy and Ovarian Suppression for Premenopausal Patients With Hormone ReceptorPositive Breast Cancer: 12-Year Results of the SOFT Trial Stenger, M. BIG 2-02 SOFT ASCO post, January 2022; https://ascopost.com/news/january-2023/adjuvant-endocrine-therapy-and-ovarian-suppression-for-premenopausal-patients-with-hr-positive-breast-cancer/ The ASCO post
2023 Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer Swain S.M.,Tan A.R., Gianni L., et al. BIG 4-11 APHINITY European Journal of Cancer, 2023, 178, p.70-81 https://doi.org/10.1016/j.ejca.2022.09.024 European Journal of Cancer
2023 Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer Nuciforo,P., Townend, J., Piccart, M.J., et al. BIG 1-06 NeoALTTO European Journal of Cancer, March 01, 2023,Vol. 181,P92-101, https://doi.org/10.1016/j.ejca.2022.12.020 European Journal of Cancer
2022 Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) Gnant M, Dueck AC, Frantal S et al. BIG 14-03 PALLAS Journal of Clinical Oncology 40, no. 3, January 20, 2022; 282-293. DOI: 10.1200/JCO.21.02554 Journal of Clinical Oncology
2022 Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant Malorni L, Tyekucheva S, Hilbers FS et al. BIG 14-04 PYTHIA Eur J Cancer.March 2022;164: 39-51. doi: 10.1016/j.ejca.2021.12.030. European Journal of Cancer
2022 Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial Lopes Cardozo JMN, Drukker CA, Rutgers EJT et al. BIG 3-04 MINDACT Journal of Clinical Oncology. Published online January 21, 2022. DOI: 10.1200/JCO.21.02019 Journal of Clinical Oncology
2022 Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: Patient level meta-analysis of 7,030 women in four randomised trials. Bradley R, Braybrooke J, Gray R et al. BIG 2-02 SOFT; BIG 3-02 TEXT Lancet Oncol 2022. doi: 10.org/10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3 Lancet Oncology
2022 Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial Gelber RD, Wang WV, Cole BF et al. BIG 4-11 APHINITY Eu J Can 166:219-228, 2022 European Journal of Cancer
2022 A phase III trial of alpelisib + trastuzumab fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer Prez-Fidalgo JA, Criscitiello C, Carrasco E et al. BIG 18-04 ALPHABET Future Oncol.Vol. 18, nr. 19, 2022 Apr 25. doi: 10.2217/fon-2022-0045. Future Oncology
2022 Code of practice needed for samples donated by trial participants Coleman R, Chan A, Barrios C et al. General Lancet Oncol. 2022 Mar;23(3):e89-e90. doi: 10.1016/S1470-2045(22)00059-6. Lancet Oncology
2022 Effect of Metformin vs Placebo on Invasive DiseaseFree Survival in Patients With Breast Cancer - The MA.32 Randomized Clinical Trial Goodwin PJ, Chen BE, Gelmon KA et al BIG 5-11 MA.32 JAMA. 2022;327(20):1963-1973. doi:10.1001/jama.2022.6147 JAMA
2022 Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 307/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study Chua BH, Link EK, Kunkler IH et al BIG 3-07 DCIS Lancet Aug 2022; 400: 43140. doi:10.1016/S0140-6736(22)01246-6 The Lancet
2022 PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer Agostinetto E, Ameye L, Martel S et al BIG 2-06 ALTTO npj Breast Cancer (2022) 8:87 ; https://doi.org/10.1038/s41523-022-00452-8 Nature
2022 Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories Ithimakin S, Parinyanitikul N, Kim S-B et al BIG Asia collaboration J Breast Cancer, 25(3):207-217, June 2022. https://doi.org/10.4048/jbc.2022.25.e21 Journal of Breast Cancer
2022 Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab Ligorio F, Di Cosimo S, Verderio P, et al. BIG 1-06 NeoALTTO J Natl Cancer Inst. Dec 8;114(12):1720-1727, 2022. doi: 10.1093/jnci/djac126. PMID: 35789270. J Natl Cancer Inst.
2022 Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapya sub-analysis of the ALTTO study Nader-Marta G, Debien V, Eiger D, Tsourti Z, et al. BIG 2 -06 ALTTO British journal of Cancer, Nov;127(10):1799-1807, November 2022. doi: 10.1038/s41416-022-01963-8. Epub 2022 Sep 1. PMID: 36050448; PMCID: PMC9643324. British Journal of Cancer
2022 Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT Prudence A. Francis,Gini F. Fleming et al. BIG 2-02 SOFT Journal of Clinical Oncology, 09 December 2022; DOI: 10.1200/JCO.22.01065 Journal of clinical Oncology
2022 Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials Pagani O.,Walley B.A.,Fleming G.F.,et al. Journal of Clinical Oncology,15 December 2022; DOI: 10.1200/JCO.22.01064 Journal of clinical Oncology
2022 Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer C.E. Geyer, J.E. Garber, R.D. Gelber, et al. BIG 6-13: Olympia Annals of Oncology,2022, Volume 33, Issue 12, p.1250-1268. https://doi.org/10.1016/j.annonc.2022.09.159. Annals of Oncology
2022 Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial Franzoi M.A., Procter M., Twelves C., et al. BIG 4-11 APHINITY Ecancer, 2022, 16:1379. https://doi.org/10.3332/ecancer.2022.1379 Ecancer
2022 Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY Trial Elisa Agostinetto/Evandro de Azambuja BIG 4-11 APHINITY
2022 Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy Lambertini, M., Fielding,S.,Loibl, S., et al. BIG 4-11 APHINITY Journal of the National Cancer Institute, August 2022, Volume 114, Issue 8, Pages 11171126,https://doi.org/10.1093/jnci/djac096 Journal of the National Cancer Institute
2021 Body Mass Index and weight change in patients with HER2-positive early breast cancer: exploratory analysis of the ALTTO BIG 2-06 trial. Martel S, Lambertini M, Agbor-Tarh D et al. BIG 2-06 ALTTO Published online on 5 January 2021. https://doi.org/10.6004/jnccn.2020.7606 JNCCN
2021 Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Piccart M, Procter M, Fumagalli D et al. BIG 4-11 APHINITY DOI: 10.1200/JCO.20.01204 Journal of Clinical Oncology. Published online on 04 February 2021. Journal of Clinical Oncology
2021 Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D) Moreno-Aspitia A, Holmes EM, Jackisch C et al. BIG 2-06 ALTTO Eur J Cancer. 2021 Mar 22;148:287-296. doi: 10.1016/j.ejca.2021.01.053. Online ahead of print. European Journal of Cancer
2021 STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial (ALTTO BIG 2-06). Sonnenblick A, Agbor-Tarh D, de Azambuja E et al. BIG 2-06 ALTTO Int J Cancer 2021 Mar 15;148(6):1529-1535. doi: 10.1002/ijc.33385 International Journal of Cancer
2021 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial (BIG 3-04) with an exploratory analysis by age. Piccart M, van t Veer LJ, Poncet C et al. BIG 3-04 MINDACT Lancet Oncol. 2021 March 12. doi: https://doi.org/10.1016/S1470-2045(21)00007-3 Lancet Oncology
2021 Tumor cellularity and infiltrating lymphocytes (CelTIL) as a survival surrogate in HER2-positive breast cancer Chic N, Luen SJ, Nuciforo P et al. BIG 1-06 NeoALTTO Journal of the National Cancer Institute, March 31 https://doi.org/10.1093/jnci/djab057 Journal of the National Cancer Institute
2021 Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study Mayer EL, Dueck AC, Martin M et al. BIG 14-03 PALLAS Lancet Oncol. Published online on 15 January 2021. doi :https://doi.org/10.1016/S1470-2045(20)30642-2 Lancet Oncology
2021 Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-The Penelope-B trial Loibl S, Marm F, Martin M et al. BIG 1-13 PENELOPE-B J Clin Oncol. 2021 Apr 1;JCO2003639. doi: 10.1200/JCO.20.03639. Online ahead of print. Journal of Clinical Oncology
2021 Overcoming barriers to clinical trials cooperation: the Breast International Group example Piccart-Gebhart MJ, Goulioti T, Straehle C and Cameron D. BIG General DOI: 10.1200/EDBK_321475American Society of Clinical Oncology Educational Book41 (April 1, 2021) 1-9. ASCO Educational Book
2021 Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer Bines J, Clark E, Barton C et al. BIG 4-11 APHINITY Br J Cancer. 2021 Apr 7. doi: 10.1038/s41416-021-01323-y. Online ahead of print. British Journal of Cancer
2021 Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study Shao Z, Tseng LM, Huang CS et al. BIG 4-11 APHINITY Jpn J Clin Oncol. 2021 Mar 3;51(3):345-353. doi: 10.1093/jjco/hyaa216 Japanese Journal of Clinical Oncology
2021 Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 Clinical Trial Leone JP, Cole BF, Regan MM et al. BIG 1-98 Cancer 2021;127(5):700-708. doi: 10.1002/cncr.33318. Epub 2020 Dec 8 Cancer
2021 Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE trial Guerini-Rocco E, Gray KP, Fumagalli C et al. BIG 1-07 SOLE Clin Cancer Res 2021;27(2):504-412. doi: 10.1158/1078-0432.CCR-20-0126. Epub 2020 Oct 20 Clinical Cancer Research
2021 Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: A report from the BIG 1-98 trial Rabaglio M, Sun Z, Maibach R et al. BIG 1-98 Breast Cancer Res Treat 2021;185(3):697-707. doi: 10.1007/s10549-020-05981-z. Epub 2020 Nov 7 Breast Cancer Research and Treatment
2021 Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer Tutt ANJ, Garber JE, Kaufman B et al. BIG 6-13 OLYMPIA N Engl J Med 2021; 384:2394-2405 DOI: 10.1056/NEJMoa2105215 New England Journal of Medicine
2021 Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative Aftimos P, Oliveira M, Irrthum A et al. BIG 14-01 AURORA Cancer Discov. 2021 Nov;11(11):2796-2811. doi: 10.1158/2159-8290.CD-20-1647. Epub 2021 Jun 28. Cancer Discovery
2021 Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer The REACT Randomized Clinical Trial Coombes RC, Tovey H, Kilburn L et al. BIG 1-03 REACT JAMA Oncol. Published online July 15, 2021. doi:10.1001/jamaoncol.2021.2193 JAMA Oncology
2021 The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32 Pimentel I, Chen BE, Lohmann AE et al. BIG 5-11 MA.32 JNCI J Natl Cancer Inst (2021) 113(2): djaa082. doi: 10.1093/jnci/djaa082 Journal of the National Cancer Institute
2021 Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial Goodwin PJ, Dowling RJO, Ennis M et al. BIG 5-11 MA.32 npj Breast Cancer. 2021; 7:74 ; https://doi.org/10.1038/s41523-021-00275-z npj Breast Cancer
2021 Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial Venet D, Rediti M, Maetens M et al. BIG 1-06 NeoALTTO Clin Cancer Res. October 15 2021;27(20):5607-5618. doi: 10.1158/1078-0432.CCR-21-1317 Clinical Cancer Research
2021 Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy Jerusalem G, Farah S, Courtois A et al. BIG 1-07 SOLE Annals of Oncology. October 2021 ; vol.32, p.1256-1266. DOI:https://doi.org/10.1016/j.annonc.2021.07.017 Annals of Oncology
2021 Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy Partridge AH, Niman SM, Ruggeri M et al. BIG 8-13 POSITIVE Breast. 2021 Aug 3; 59:327-338. doi: 10.1016/j.breast.2021.07.021. The Breast
2020 Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial Cuzick J, Sestak I, Forbes JF et al. BIG 5-02 IBIS-II Lancet. 2020 Jan 11; doi: 10.1016/S0140-6736(19)32955-1. The Lancet
2020 Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial Delaloge S, Piccart M, Rutgers E et al. BIG 3-04 MINDACT J Clin Oncol. 2020 Feb 21; doi: 10.1200/JCO.19.01371. Journal of Clinical Oncology
2020 Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. Eiger D, Pond NF, Agbor-Tarh D et al. BIG 2-06 ALTTO Br J Cancer. 2020 Mar 16. doi: 10.1038/s41416-020-0786-x. [Epub ahead of print] British Journal of Cancer
2020 Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis Zambelli A, Pappagallo G, Marchetti P. BIG 4-11 APHINITY J Comp Eff Res. 2020 Feb 14. doi: 10.2217/cer-2019-0168. Journal of comparative effectiveness research
2020 Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial King MT, Link EK, Whelan TJ et al. BIG 3-07 DCIS Lancet Oncol. 2020 Mar 20. pii: S1470-2045(20)30085-1. doi: 10.1016/S1470-2045(20)30085-1. Lancet Oncology
2020 High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer Qiu SQ, van Rooijen J, Nienhuis HH et al. BIG 2-07 Male BC Breast Cancer Res. 2020 Mar 18;22(1):30. doi: 10.1186/s13058-020-01266-x. Breast Cancer Research
2020 The legacy of Professor Aron Goldhirsch. A Gelber RD, Coates AS, Gelber S et al. General Ann Oncol 2020;31(6):671-673. doi: 10.1016/j.annonc.2929.03.288. Epub 2020 Mar 23 Annals of Oncology
2020 Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy Di Cosimo S, Appierto V, Pizzamiglio S et al. BIG 1-06 NeoALTTO Int J Mol Sci. 2020 Feb 18;21(4). pii: E1386. doi: 10.3390/ijms21041386. International Journal of Molecular Sciences
2020 Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors Piccart MJ, Hilbers FS, Bliss JM et al. BIG-NABCG collaboration DOI: 10.1200/JCO.20.01382 Journal of Clinical Oncology. Published online October 14, 2020. Journal of Clinical Oncology
2020 STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial Sonnenblick A, Agbor-Tarh D, de Azambuja E et al. BIG 2-06 ALTTO Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33385. Online ahead of print.PMID: 33152119 International Journal of Cancer
2020 Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial Lambertini M, Agbor-Tarh D, Metzger-Filho O et al. BIG 2-06 ALTTO ESMO Open. 2020; 5(6): e000979. Published online on 4 November 2020. doi: 10.1136/esmoopen-2020-000979 ESMO Open
2020 Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study Luen SJ, Asher R, Lee CK et al. BIG 1-98 Ann Oncol 2020;31(10):1359-1365. doi: 10.1016/j.annonc.2020.06.024 Epub 2020 July 8 Annals of Oncology
2020 Estimation of historical control rate for a single arm de-escalation study Application to the POSITIVE trial Sun Z, Niman SM, Pagani O et al. BIG 8-13 POSITIVE Breast 2020;53:1-7. doi: 10.1016/j.breast.2020.05.012. Epub 2020 Apr 9 Breast
2020 Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TEXT and SOFT Pagani O, Francis PA, Fleming GF et al. BIG 2-02 SOFT; BIG 3-02 TEXT J Clin Oncol 2020;38(12):1293-1303. doi: 10.1200/JCO.18.01967. Epub 2019 Oct 16. Journal of Clinical Oncology
2019 Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Pena L, Izquierdo M, Huober J, Baselga J, Piccart M, De Braud FG, Apolone G, Verderio P, Daidone MG. BIG 1-06 NeoALTTO 2019 Jul 1;25(13):3887-3895 doi: 10.1158/1078-0432.CCR-18-2507 Clinical Cancer Research
2019 Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Mller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J, SOLE Investigators. BIG 1-07 SOLE Br J Cancer. 2019 Apr 10. doi: 10.1038/s41416-019-0435-4 British Journal of Cancer
2019 Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study Kirschbrown WP, Kgedal M1, Wang B1, Lindbom L2, Knott A3, Mack R3, Monemi S1, Nijem I1, Girish S1, Freeman C4, Fumagalli D5, McConnell R6, Jerusalem G7, Twelves C8, Baselga J9, von Minckwitz G10, Bines J11, Garg A12. BIG 4-11 APHINITY Cancer Chemother Pharmacol. 2019 Apr 11. doi: 10.1007/s00280-019-03826-1 Cancer Chemotherapy and Pharmacology
2019 Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer Luo Y, Li W, Jiang Z, Zhang Q, Wang L, Mao Y, Tjan-Heijnen VCG, Im SA, McConnell R, Bejarano S, Fumagalli D, Bines J, Wang B, Garg A, Kirschbrown WP, Xu B BIG 4-11 APHINITY Anticancer Drugs. 2019 Sep;30(8):866-872. doi: 10.1097/CAD.0000000000000808 Anticancer Drugs
2019 Analytical validation of a standardized scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicenter collaboration Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M; International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG). BIG-NABCG collaboration Histopathology. 2019 Apr 24. doi: 10.1111/his.13880. Histopathology
2019 Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial Roth F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M. BIG 1-06 NeoALTTO Clin Cancer Res. 2019 Mar 12. doi: 10.1158/1078-0432.CCR-18-2521. Clinical Cancer Research
2019 Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber RD, de Azambuja E, Ignatiadis M BIG 1-06 NeoALTTO & BIG 2-06 ALTTO Cancer. 2019 Jan 15 doi: 10.1002/cncr.31784. Cancer
2019 Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E BIG 2-06 ALTTO Breast Cancer Res Treat. 2019 May 27 doi: 10.1007/s10549-019-05284-y Breast Cancer Research and Treatment
2019 Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Pea L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. BIG 1-06 NeoALTTO Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy530. Annals of Oncology
2019 Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98 Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thrlimann B, Colleoni M, Viale G, Brown M, Tamimi RM. BIG 1-98 Breast Cancer Res. 2019 Feb 22 doi: 10.1186/s13058-019-1118-z. Breast Cancer Research
2019 Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, Andr F BIG 4-13 PANACEA Lancet Oncol 2019 March; doi: 10.1016/S1470-2045(18)30812-X. The Lancet Oncology
2019 Prognostic value of progresterone receptor by subtype in patients with estrogen receptor-positive, HER-2 negative breast cancer Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Bouckaert O, Wildiers H, Floris G, van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thrlimann B, Vergote I, Christodoulou E, van Calster B, Neven P. BIG 1-98 Oncologist 2019 Feb 24; doi: 10.1634/theoncologist.2018-0176. Oncologist
2019 Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO Trial Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber RD BIG 2-06 ALTTO Ann Oncol. 2019 Jun 26.; doi: 10.1093/annonc/mdz195. Annals of Oncology
2019 Survival outcomes of the NeoALTTO study (BIG 106): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer Huober J., Holmes E., Baselga J., de Azambuja E., Untch M., Fumagalli F., Sarp S., Lang I., Smith I., Boyle F., Xu B., Lecocq C., Wildiers H., Jouannaud C., Hackman J., Dasappa L., Ciruelos E., Carlos Toral Pena J., Adamchuk H., Hickish T., de la Pena L., Jackisch C., Gelber R. D., Piccart-Gebhart M., Di Cosimo S. BIG 1-06 NeoALTTO Eur J Cancer. 2019 Sept. DOI: 10.1016/j.ejca.2019.04.038 European Journal of Cancer
2019 Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Pea L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E BIG 3-13 LORELEI Lancet Oncol. 2019 Sep;20(9):1226-1238. doi: 10.1016/S1470-2045(19)30334-1. Epub 2019 Aug 8. The Lancet Oncology
2019 The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Pea L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Tagliabue E. BIG 1-06 NeoALTTO Eur J Cancer. 2019 Sep;118:1-9. doi: 10.1016/j.ejca.2019.06.001 European Journal of Cancer
2019 Missed opportunities and challenges for surgical breast cancer research in the era of personalized cancer treatment Rubio IT, Kontos M, Vrancken-Peeters M, Rouzier R, Skandarajah AR, Galimberti V, Kroman N, Caballero C, Ohno S; BIG Task Force Surgical Trials BIG Task Force Surgical Trials Eur J Surg Oncol. 2019 Nov 20. pii: S0748-7983(19)31447-7. doi: 10.1016/j.ejso.2019.11.503 European Journal of Surgical Oncology
2019 Lucitanib for the Treatment of HR+/HER2? Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study Hui R, Pearson A, Cortes J, Campbell C, Poirot C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G. BIG 2-13 FINESSE Clin Cancer Res 2019 Oct 16 DOI: 10.1158/1078-0432.CCR-19-1164 Clin Cancer Res. 2020 Jan 15;26(2):354-363. doi: 10.1158/1078-0432.CCR-19-1164. Epub 2019 Oct 16. Clinical Cancer Research
2019 Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TEXT and SOFT Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Lang I, Gomez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM BIG 2-02 SOFT; BIG 3-02 TEXT J Clin Oncol. doi: 10.1200/JCO.18.01967. 2019 Oct 16. Journal of Clinical Oncology
2019 Independent validation of EarlyR gene signature in BIG 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer Buechler S, Gray KP, Gkmen-Polar Y, Willis S, Thrlimann B, Kammler R, Viale G, Leyland-Jones B, Badve* SS, Regan* MM. *Co-last authors. BIG 1-98 JNCI Cancer Spectr. doi: 10.1093/jncics/pkz051. Epub 2019 Aug 16. JNCI Cancer Spectrum
2019 Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, Van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber R, Piccart M, Mobus V, de Azambuja E, on behalf of the APHINITY Steering Committee and Investigators BIG 4-11 APHINITY Clin Breast Cancer. 2019 Sep 5 doi: 10.1016/j.clbc.2019.06.016. Clinical Breast Cancer
2019 Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia Sestak I, Blake G M, Patel R, Coleman R E, Cuzick J, Eastell R BIG 5-02 IBIS-II Bone. 2019 Jul;124:83-88. doi: 10.1016/j.bone.2019.04.016 Bone
2019 An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06) Emanuela Risi, Chiara Biagioni, Matteo Benelli, Ilenia Migliaccio, Amelia McCartney, Martina Bonechi, Cristina Guarducci, Florentine Hilbers, Serena Di Cosimo, Jens Huober, Dario Romagnoli, Giulia Boccalini, Stefania Vitale, Christos Sotiriou, Laura Biganzoli, Angelo Di Leo, and Luca Malorni BIG 1-06 NeoALTTO Ther Adv Med Oncol. 2019; 11: 1758835919891608. Therapeutic Advances in Medical Oncology
2019 Adjuvant systemic treatment of premenopausal women with hormone receptorpositive early breast cancer: Lights and shadows Regan MM, Fleming GF, Walley B, Francis PA, Pagani O. BIG 2-02 SOFT; BIG 3-02 TEXT J Clin Oncol 2019 April 10;37(11)862-866. doi: 10.1200/JCO.18.02433. Epub 2019 Feb 27 Journal of Clinical Oncology
2019 Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thrlimann B, Mehta K, Blohmer JU, Colleoni M, Mller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G. BIG 1-98 Breast Cancer Res Treat 2019 Aug;176(3:557-568. doi:10.1007/s10549-018-05112-9. Epub 2019 May 7 Breast Cancer Research and Treatment
2019 International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast Olivotto IA, Link E, Phillips C, Whelan TJ, et al. BIG 3-07 DCIS Radiotherapy and Oncology. Volume 142, P180-185, January 01, 2020. Published online on August 17, 2019. doi:https://doi.org/10.1016/j.radonc.2019.07.024. Radiotherapy and Oncology
2019 A pooled analysis of the cardiac events in the trastuzumab adjuvant trials de Azambuja E, Ponde N, Procter M et al. BIG 1-01 HERA Breast Cancer Res Treat. 2020 Jan;179(1):161-171. doi: 10.1007/s10549-019-05453-z. Epub 2019 Oct 11 Breast Cancer Research and Treatment
2019 Post-mastectomy radiation therapy in human epidermal growth factor receptor 2 positive breast cancer patients: Analysis of the HERA trial Abi Jaoude J, de Azambuja E, Makki M et al. BIG 1-01 HERA Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):503-510. doi: 10.1016/j.ijrobp.2019.10.022. Epub 2019 Oct 22. International Journal of Radiation Oncology. Biology. Physics.
2019 Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA trial. Sonnenblick A, Bailey A, Uziely B et al. BIG 1-01 HERA Anticancer Res. 2019 Feb;39(2):797-802. doi: 10.21873/anticanres.13177 Anticancer Research
2018 Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schrder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litire S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH. BIG 2-07 Male BC Ann Oncol. 2018 Feb 1;29(2):405-417. doi: 10.1093/annonc/mdx651. Annals of Oncology
2018 Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators BIG 1-01 HERA Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12. Clinical Cancer Research
2018 The Final Verdict: Chemotherapy Benefits Estrogen Receptor-Negative Isolated Local Recurrence. Chan N, Toppmeyer DL. BIG 1-02 CALOR J Clin Oncol. 2018 Apr 10, doi: 10.1200/JCO.2017.77.4877. Journal of Clinical Oncology
2018 Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martn M, Nortier JWR, Paterson AHG, Rimawi MF, Lng I, Baena-Caada JM, Thrlimann B, Mamounas EP, Geyer CE Jr, Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S; International Breast Cancer Study Group; NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch Breast Cancer Trialists' Group; Breast International Group. BIG 1-02 CALOR J Clin Oncol. 2018 Feb 14 doi: 10.1200/JCO.2017.76.5719. Journal of Clinical Oncology
2018 Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C. BIG 1-06 NeoALTTO JAMA Oncol. 2018 Jun 14:e181564. doi: 10.1001/jamaoncol.2018.1564. JAMA Oncology
2018 Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06) Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart M, Suter T, de Azambuja E. BIG 1-06 NeoALTTO Breast Cancer Res Treat. 2018 Apr;168(3):631-638. doi: 10.1007/s10549-017-4628-3. Breast Cancer Research and Treatment
2018 Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial Ignatiadis M, Silva MJ, Campbell C, Bradbury I, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Sotiriou C, Loi S, Roth F, Dawson S BIG 1-06 NeoALTTO DOI: 10.1158/1538-7445.SABCS17-PD3-03 Published February 2018 Cancer Research
2018 Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial D Venet, F Roth, F Dupont, M Maetens, D Fumagalli, R Salgado, I Bradbury, L Pusztai, N Harbeck, M Izquierdo, L de la Pena, M Ignatiadis, E de Azambuja, J Huober, P Nuciforo, J Baselga, M Piccart, S Loi and C Sotiriou BIG 1-06 NeoALTTO DOI: 10.1158/1538-7445.SABCS17-P2-05-04 Published February 2018 Cancer Research
2018 Identifying clinically relevant subgroups of women with HER2-positive breast cancer: An analysis of Neo-ALTTO using the 41-gene TRAR score Di Cosimo S, Triulzi T, De Cecco L, Pizzamiglio S, de Azambuja E, Fumagalli D, Pusztai L, Harbeck N, Izquierdo M, de la Pena L, Huober J, Baselga J, Piccart M, Verderio P, Tagliabue E BIG 1-06 NeoALTTO DOI: 10.1158/1538-7445.SABCS17-P2-09-03 Published February 2018 Cancer Research
2018 Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer DL Rimm, D Carvajal-Hausdorf, N Harbeck, D Fumagalli, V Rodrik-Outmezguine, L delaPena, E deAzambuja, J Huober, J Baselga, M Piccart, E Holmes and L Pusztai BIG 1-06 NeoALTTO DOI: 10.1158/1538-7445.SABCS17-P2-09-07 Published February 2018 Cancer Research
2018 T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial R Powles, D Redmond, C Sotiriou, S Loi, D Fumagalli, P Nuciforo, N Harbeck, E de Azambuja, S Sarp, S Di Cosimo, J Huober, J Baselga, M Piccart-Gebhart, O Elemento, C Hatzis and L Pusztai BIG 1-06 NeoALTTO DOI: 10.1158/1538-7445.SABCS17-P2-09-01 Cancer Research
2018 The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart M, Baselga J, de Azambuja E BIG 1-06 NeoALTTO Eur J Cancer. 2018 Jan; doi: 10.1016/j.ejca.2017.10.036. Epub 2017 Dec 8. European Journal of Cancer
2018 A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06). Risi E, Biagioni C, Benelli M, Migliaccio I, McCartney A, Bonechi M, Guarducci C, Hilbers F, Di Cosimo S, Baselga J, Romagnoli D, Boccalini G, Vitale S, Grilli A, Bicciato S, Sotiriou C, Biganzoli L, Di Leo A, Malorni L BIG 1-06 NeoALTTO DOI: 10.1200/JCO.2018.36.15_suppl.570 Journal of Clinical Oncology
2018 Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials. Saranya Chumsri, Daniel Serie, Afshin Mashadi-Hossein, Jennifer M. Kachergus, Sarah Warren, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Dooren, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Jose Baselga, Christos Sotiriou, Edith A. Perez, Amylou C. Dueck, Alvaro Moreno-Aspitia, E Aubrey Thompson BIG 1-06 NeoALTTO DOI: 10.1200/JCO.2018.36.15_suppl.577 Journal of Clinical Oncology
2018 Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers F, Schuehly U, Korde L, Azim H. A., Di Cosimo S, Tenglin R. C., Bodo Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M. J., Gelber R. D., De Azambuja E., Ignatiadis M BIG 1-06 NeoALTTO & BIG 2-06 ALTTO DOI: 10.1200/JCO.2018.36.15_suppl.10065 Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 10065-10065. Journal of Clinical Oncology
2018 Rethinking Extended Adjuvant Antiestrogen Therapy to Increase Survivorship in Breast Cancer Abderrahman B, Jordan VC BIG 1-07 SOLE JAMA Oncol. 2018 Jan doi: 10.1001/jamaoncol.2017.3510. JAMA Oncology
2018 Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavil J, Kuroi K, Marth C, Mller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators. BIG 1-07 SOLE 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17 The Lancet Oncology
2018 Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Nyandoto P, Villman KK, Halonen P, Granstam-Bjrneklett H, Lundgren L, Sailas L, Turpeenniemi-Hujanen T, Tanner M, Yachnin J, Ritchie D, Johansson O, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H. BIG 1-10 SOLD JAMA Oncol. 2018 May 31. doi: 10.1001/jamaoncol.2018.1380 JAMA Oncology
2018 Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thrlimann B, Colleoni M, Cuzick J. BIG 1-98 J Clin Oncol. 2018 Apr 20 doi: 10.1200/JCO.2017.76.4258. Journal of Clinical Oncology
2018 Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. Lykkesfeldt AE, Iversen BR, Jensen MB, Ejlertsen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T, Rasmussen BB BIG 1-98 Acta Oncol. 2018 Jan doi: 10.1080/0284186X.2017.1404126. Acta Oncologica
2018 Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone ReceptorPositive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Lang I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thurlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. BIG 1-98 J Clin Oncol. doi: 10.1200/JCO.18.0044. 2018 Nov 26. Journal of Clinical Oncology
2018 Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lng I, Gmez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. BIG 2-02 SOFT; BIG 3-02 TEXT N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMoa1803164. New England Journal of Medicine
2018 Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart M, Gelber RD, de Azambuja E BIG 2-06 ALTTO J Natl Cancer Inst. 2018 Jun 5. doi: 10.1093/jnci/djy094. Journal of the National Cancer Institute
2018 Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes C F. Spraggs, LR Parham, L P Briley, L Warren, L S Williams, D Fraser, Z Jiang, Z Aziz, S Ahmed, G Demetrious, Z Tong, A O. Mehta, N Jackson, J Byrne, M Andersson, M Toi, L Harris, J Gralow, JA Zujewski, R Crescenzo, A Armour, E Perez, M Piccart BIG 2-06 ALTTO Pharmacogenomics J. 2018 May 22;18(3):480-486. doi: 10.1038/tpj.2017.39. Pharmacogenomics Journal
2018 Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial Martel S, Lambertini M, Agbor-Tarh D, Ponde N, Gombos A, Paterson V, Hilbers F, Korde L, Manukyants A, Dueck A. C., Maurer C, Piccart-Gebhart M. J., Moreno-Aspitia A, Desmedt C, Di Cosimo S, De Azambuja E BIG 2-06 ALTTO DOI: 10.1200/JCO.2018.36.15_suppl.10067 Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 10067-10067. Journal of Clinical Oncology
2018 Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J. BIG 2-98 TAX 315 Ann Oncol. 2018 Apr 1;29(4):1056-1062. doi: 10.1093/annonc/mdx730. Annals of Oncology
2018 Immune Infiltration in Invasive Lobular Breast Cancer Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Roth F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C. BIG 2-98 TAX 315 J Natl Cancer Inst. 2018 Jul 1;110(7):768-776. doi: 10.1093/jnci/djx268 Journal of the National Cancer Institute
2018 Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial Zeidan YH,Habib JG,Ameye L,Paesmans M,de Azambuja E,Gelber RD,Campbell I,Nordenskjld B,Gutirez J,Anderson M,Lluch A,Gnant M,Goldhirsch A,Di Leo A,Joseph DJ,Crown J,Piccart-Gebhart M,Francis PA. BIG 2-98 TAX 315 Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):316-324. doi: 10.1016/j.ijrobp.2018.01.105. International Journal of Radiation Oncology
2018 p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. Sonnenblick A, Salgado R, Brohe S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, de Azambuja E, Lieveke A, Piccart MJ, Bromberg JF, Sotiriou C BIG 2-98 TAX 315 Int J Oncol. 2018 Feb; doi: 10.3892/ijo.2017.4212. Epub 2017 Nov 27. International Journal of Oncology
2018 Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Lng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thrlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. BIG 1-98 J Clin Onco 2019 Jan 10; doi: 10.1200/JCO.18.00440. Journal of Clinical Oncology
2018 Association of somatic driver alterations with prognosis in postmenopausal, hormone receptor-positive, HER2-negative early breast cancer: A secondary analysis of the BIG 1-98 randomized clinical trial Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, JeBailey L, Dolan S, Hackl W, Thrlimann B, Viale G, Colleoni M, Regan MM, Loi S. BIG 1-98 JAMA Oncol 2018 Oct 1; doi: 10.1001/jamaoncol.2018.1778. Jama Oncology
2018 Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thrlmann B, Colleoni M, Cuzick J. BIG 1-98 CTS5. J Clin Oncol 2018 Jul 1; doi: 10.1200/JCO.2017.76.4258 Journal of Clinical Oncology
2018 Tailoring adjuvant endocrine therapy for premenopausal breast cancer Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lng I, Gmez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer Jr. CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio?Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A**, Regan MM**, the SOFT and TEXT Investigators and the International Breast Cancer Study Group. BIG 2-02 SOFT; BIG 3-02 TEXT N Engl J Med 2018 Jul 12; doi: 10.1056/NEJMoa1803164 New England Journal of Medicine
2018 A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy M, Von Moos R, Corts J, Vidal MJ, Hennessy B, Walshe J, Parraga KA, Ribi K, Bernhard J, Murillo SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G; International Breast Cancer Study Group, Cancer Trials Ireland and SOLTI Group BIG 2-12 SNAP Ann Oncol. 2018 Mar 1;29(3):661-668. doi: 10.1093/annonc/mdx772 Annals of Oncology
2018 Exploratory analysis of single-gene predictive biomarkers in HERA DASL cohort reveals that C8A mRNA expression is prognostic of outcome and predictive of benefit of trastuzumab Willis S, Polydoropoulou V, Sun Y et al. BIG 1-01 HERA JCO Precis Oncol. 2018; 2: PO.18.00016. Published online 2018 Nov 1. doi: 10.1200/PO.18.00016 JCO Precision Oncology
2017 Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, Dijkstra NH, Schrder CP, van Asperen CJ, Linderholm B, Benstead K, Foekens R, Martens JWM, Bartlett JMS, van Deurzen CHM. BIG 2-07 Male BC Eur J Cancer. 2017 Sep;82:219-227 European Journal of Cancer
2017 Male breast cancer: finding the way in this uncommon path. Maurer C, Martel S, de Azambuja E BIG 2-07 Male BC ESMO Open. 2017 Mar 16; doi: 10.1136/esmoopen-2017-000169. eCollection 2017. ESMO Open
2017 Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program Doebar SC, Slaets L, Cardoso F, Giordano SH, Bartlett JM, Tryfonidis K, Dijkstra NH, Schrder CP, van Asperen CJ, Linderholm B, Benstead K, Dinjens WN, van Marion R, van Diest PJ, Martens JW, van Deurzen CH, BIG 2-07 Male BC Mod Pathol. 2017 Apr;30(4):509-518 Modern Pathology
2017 Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT Randomised EuropeAn celecoxib trial) RC Coombes, H Tovey, L Kilburn, J Mansi, C Palmieri, J Bartlett, J Hicks, A Makris, A Evans, S Loibl, C Denkert, E Murray, R Grieve, R Coleman, M Schmidt, P Klare, M Rezai, B Rautenberg, N Klutinus, U Rhein, K Mousa, S Ricardo-Vitorino, G von Minckwitz and J Bliss BIG 1-03 REACT DOI: 10.1158/1538-7445.SABCS17-GS3-03 Published February 2018 Cancer Research
2017 11 years' follow-up of trastuzumab after adjuvant chemothera-py in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team BIG 1-01 HERA Lancet 2017 Mar 25 doi: 10.1016/S0140-6736. The Lancet Oncology
2017 Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VH, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. BIG 1-01 HERA Ann Oncol. 2017 Mar 31. doi: 10.1093/annonc/mdx152. [Epub ahead of print] Annals of Oncology
2017 Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, Al-Sakaff N, Piccart-Gebhart MJ, de Azambuja E. BIG 1-01 HERA J Clin Oncol. 2017 Mar 10;35(8):878-884. doi: 10.1200/JCO.2015.65.7916. Epub 2016 Oct 23. Journal of Clinical Oncology
2017 Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, Gomis RR. BIG 1-04 AZURE Lancet Oncol. 2017 Nov;18 doi: 10.1016/S1470-2045(17)30603-4. Epub 2017 Oct 13. The Lancet Oncology
2017 HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Samira M, Brohe S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CL. BIG 1-06 NeoALTTO Clin Cancer Res. 2017 Apr 5. doi: 10.1158/1078-0432.CCR-16-2287 Clinical Cancer Research
2017 The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, Laes JF, Campbell PJ, Thompson A, Cortes J, Seiler S, Vinnicombe S, Oliveira M, Roth F, Bareche Y, Fumagalli D, Zardavas D, Desmedt C, Piccart M, Loi S, Sotiriou C. BIG 14-01 AURORA NPJ Breast Cancer. 2017 Jun 29;3:23. doi: 10.1038/s41523-017-0026-6. eCollection 2017 npj Breast Cancer
2017 PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase Ill trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer E.L. Mayer, A.M. Demichele, G. Pfeiler, W. Barry, O. Metzger, P. Rastogi, F. Symmans, H.J. Burstein, K. Miller, S. Loibl, S. Schmatloch, T. Goulioti, D. Zardavas, C. Fesl, M. Koehler, C. Huang Bartlett, X. Huang, M. Piccart, E.P. Winer, M. Gnant BIG 14-03 PALLAS Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362 Annals of Oncology
2017 Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98 Alkner S, Jensen MB, Rasmussen BB, Bendahl PO, Fern M, Rydn L, Mouridsen H; Danish Breast Cancer Cooperative Group. BIG 1-98 Breast Cancer Res Treat. 2017 Nov;166(2):481-490. Breast Cancer Research and Treatment
2017 High expression of FGD3, a putative regulator of cell morphology and motility, is prognostic of favorable outcome in multiple cancers Willis S, Sun Y, Abramovitz M, Fei T, Young B, Lin X, Ni M, Achua J, Regan MM, Gray KG, Gray R, Wang V, Long B, Kammler R, Sparano JA, Williams C, Goldstein LJ, Salgado R, Loi S, Pruneri G, Viale G, Brown M, Leyland-Jones B. BIG 1-98 J Clin Oncol Precis Oncol. doi: 10.1200/PO.17.00009. 2017 October 13. Journal of Clinical Oncology Precision Oncology
2017 HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thrlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG). BIG 1-98 Eur J Cancer. 2017 Jul;79:129-138. doi: 10.1016/j.ejca.2017.03.033. Epub 2017 May 8. European Journal of Cancer
2017 Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. Borgquist S, Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Lang I, Debled M, Ejlertsen B, von Moos R, Smith I, Coates AS, Goldhirsch A, Rabaglio M, Price KN, Gelber RD, Regan MM, Thurlimann B. BIG 1-98 J Clin Oncol. 35:1179-1188, 2017 (IBCSG 18-98) Journal of Clinical Oncology
2017 A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis L H Weischenfeldt K, Kirkegaard T, Rasmussen BB, Giobbie-Hurder A, Jensen MB, Ejlertsen B, Lykkesfeldt AE BIG 1-98 Acta Oncol. 2017 May 10:1-7. doi: 10.1080/0284186X.2017.1324211. Acta Oncologica
2017 Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials Saha P1, Regan MM1, Pagani O1, Francis PA1, Walley BA1, Ribi K1, Bernhard J1, Luo W1, Gmez HL1, Burstein HJ1, Parmar V1, Torres R1, Stewart J1, Bellet M1, Perell A1, Dane F1, Moreira A1, Vorobiof D1, Nottage M1, Price KN1, Coates AS1, Goldhirsch A1, Gelber RD1, Colleoni M1, Fleming GF1; SOFT; TEXT Investigators; International Breast Cancer Study Group. BIG 2-02 SOFT; BIG 3-02 TEXT J Clin Oncol. 2017 Jun 27:JCO2016720946. doi: 10.1200/JCO.2016.72.0946. Journal of Clinical Oncology
2017 Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT Regan MM, Walley BA, Francis PA, Fleming GF, Lng I, Gmez HL, Colleoni M, Tondini C, Pinotti G, Salim M, Spazzapan S, Parmar V, Ruhstaller T, Abdi EA, Gelber RD, Coates AS, Goldhirsch A, Pagani O BIG 2-02 SOFT; BIG 3-02 TEXT Ann Oncol 0: 1-8, 2017. First published online July 29, 2017 Annals of Oncology
2017 Adjuvant endocrine therapy for premenopausal women: Type and duration Francis PA. BIG 2-02 SOFT; BIG 3-02 TEXT E-published Breast 2017 June 29 Breast
2017 The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer J. S. Thomas, A. M. Hanby, N. Russell, G. van Tienhoven, K. Riddle, N. Anderson, D. A. Cameron, J. M. S. Bartlett, T. Piper, C. Cunningham, P. Canney, I. H. Kunkler, and On behalf of the SUPREMO Trial Management Group BIG 2-04 SUPREMO Breast Cancer Res Treat. 2017; doi: 10.1007/s10549-017-4145-4 Breast Cancer Research and Treatment
2017 Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) M. Lambertini C. Campbell J. Bines L. Korde M.A. Izquierdo Delso D. Fumagalli K. Pritchard A. Wolff C. Jackisch I. Lang M. Untch I. Smith F.M. Boyle B. Xu C.H. Barrios J. Baselga A. Moreno-Aspitia M. Piccart R. Gelber E. De Azambuja BIG 2-06 ALTTO Ann Oncol. 2017 Sept 1 doi: 10.1093/annonc/mdx362.009 Annals of Oncology
2017 Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial Sonnenblick A., Agbor-Tarh D., Bradbury I., Di Cosimo S., Azim H. A., Fumagalli D., Sarp S., Wolff A. C., Andersson M., Kroep J., Cufer T., Simon S. D., Salman P., Toi M., Harris L., Gralow J., Keane M., Moreno-Aspitia A., Piccart-Gebhart M., de Azambuja E. BIG 2-06 ALTTO J Clin Oncol. 2017 May 1;35(13):1421-1429. doi: 10.1200/JCO.2016.69.7722. Epub 2017 Mar 13. Journal of Clinical Oncology
2017 Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T?L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer. A Moreno-Aspitia, E McCormick Holmes, C Jackisch, E De Azambuja, F. M. Boyle, D W. Hillman, BIG 2-06 ALTTO J Clin Oncol. doi: 10.1200/JCO.2017.35.15_suppl.502 Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 502-502. Journal of Clinical Oncology
2017 Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program F Cardoso, J M S Bartlett, L Slaets, C H M van Deurzen, E van Leeuwen-Stok, P Porter, B Linderholm, I Hedenfalk, C Schrder, J Martens, J Bayani, C van Asperen, M Murray, C Hudis, L Middleton, J Vermeij, K Punie, J Fraser, M Nowaczyk, I T Rubio, S Aebi, C Kelly, K J Ruddy, E Winer, C Nilsson, L Dal Lago, L Korde, K Benstead, O Bogler, T Goulioti, A Peric, S Litire, K C Aalders, C Poncet, K Tryfonidis, S H Giordano BIG 2-07 Male BC Ann Oncol. 2017 Oct 28. doi: 10.1093/annonc/mdx651. Annals of Oncology
2017 A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial Gennari A, Sun Z, Hasler-Strub U, Colleoni M, Kennedy MJ, Von Moos R, Corts J, Vidal MJ, Hennessy B, Walshe J, Amillano Parraga K, Ribi K, Bernhard J, Morales SM, Pagani O, Barbeaux A, Borstnar S, Rabaglio-Poretti M, Maibach R, Regan MM, Jerusalem G. BIG 2-12 SNAP Ann Oncol. 2017 Dec 8. doi: 10.1093/annonc/mdx772. Annals of Oncology
2017 Long-term follow-up of the intergroup exemestane study Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lnning PE, Ortmann O, Snowdon C, Van de Velde CJH, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC BIG 2-97 IES J Clin Oncol 2017; doi: 10.1200/JCO.2016.70.5640. Journal of Clinical Oncology
2017 Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. Viale G, de Snoo FA, Slaets L, Bogaerts J, van t Veer L, Rutgers EJ, Piccart-Gebhart M, Stork-Sloots L, Glas A, Russo L, DellOrto P, Tryfonidis K, Litire S, Cardoso F BIG 3-04 MINDACT Breast Cancer Res Treat. 2018 Jan; doi: 10.1007/s10549-017-4509-9. Epub 2017 Sep 19. Breast Cancer Research and Treatment
2017 Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. Aalders KC, Kuijer A, Straver ME, Slaets L, Litiere S, Viale G, Vant Veer LJ, Glas AM, Delorenzi M, van Dalen T, Tryfonidis K, Piccart-Gebhart M, Cardoso F, Rutgers EJ BIG 3-04 MINDACT Eur J Cancer. 2017 Jul doi: 10.1016/j.ejca.2017.03.034. Epub 2017 May 3. European Journal of Cancer
2017 Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. BIG 4-11 APHINITY N Engl J Med. 2017 Jul 13 doi: 10.1056/NEJMoa1703643. New England Journal of Medicine
2017 Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kmmel S, Steger G, Gombos A, Lux M, Piccart-Gebhart M, Von Minckwitz G, Baselga J, Loi S BIG 6-11 Neo-PHOEBE Eur J Cancer. 2017 Nov; doi: 10.1016/j.ejca.2017.08.020. Epub 2017 Sep 17. European Journal of Cancer
2017 De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017 Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thrlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, Andr F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. St Gallen Consensus Ann Oncol 2017 doi: 10.1093/annonc/mdx308 Annals of Oncology
2017 Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer Rosenberg SM, Gelber S, Gelber RD, Krop E, Korde LA, Pagani O, Partridge AH. BIG 8-13 POSITIVE J Adolesc Young Adult Oncol. 2017 Sep;6 doi: 10.1089/jayao.2017.0031. Journal of Adolescent and Young Adult Oncology
2017 Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial Gingras I, Holmes E, De Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart MJ, Azim HA Jr BIG 2-06 ALTTO J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw331. Journal of the National Cancer Institute
2017 Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E. BIG 2-06 ALTTO J Clin Oncol. 2017 May 1; doi: 10.1200/JCO.2016.69.7722 Journal of Clinical Oncology
2016 Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: investigating innate immunity as a tumor suppressor in breast cancer. Touati N, Tryfonidis K, Caramia F, Bonnefoi H, Cameron D, Slaets L, Parker B, Loi S. BIG 1-00 p53 Eur J Cancer 2016; 72 (72):95-102. 10.10161/j.ejca.2016.11.015 European Journal of Cancer
2016 Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rschoff J0, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B. BIG 1-01 HERA JAMA Oncol. 2016 Apr 21. doi: 10.1001/jamaoncol.2016.0339. [Epub ahead of print] JAMA Oncology
2016 Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart M, Gelber RD for the HERA Study Team. BIG 1-01 HERA Breast Cancer Res Treat 155:127-132, 2016. (IBCSG 28-02) Breast Cancer Research and Treatment
2016 Poor prognosis after second locoregional recurrences in the CALOR trial. Wapnir IL, Gelber S, Anderson SJ, Mamounas EP, Robidoux A, Martn M, Nortier JW, Geyer CE Jr, Paterson AH, Lng I, Price KN, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S; CALOR trial investigators. BIG 1-02 CALOR Ann Surg Oncol. 2016 Sep 23. [Epub ahead of print] Annals of Surgical Oncology
2016 Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial W. Shi, T. Jiang, P. Nuciforo, C. Hatzis, E. Holmes, N. Harbeck, C. Sotiriou, L. Pea, S. Loi, D. D. Rosa, S. Chia, A. Wardley, T. Ueno, J. Rossari, H. Eidtmann, A. Armour, M. Piccart-Gebhart, D. L. Rimm, J. Baselga, L. Pusztai. BIG 1-06 NeoALTTO ANNALS OF ONCOLOGY 2016 Sept 29, pii: mdw434 Annals of Oncology
2016 PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J. BIG 1-06 NeoALTTO Ann Oncol. 2016 Aug;27(8):1519-25. doi: 10.1093/annonc/mdw197. Epub 2016 May 13. Annals of Oncology
2016 Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO Di Cosimo S, Appierto V, Tiberio P, Verderio P, Pizzamiglio S, Bottelli S, Iorio M, Baselga J, Piccart M, Huober J, Brase J, de la Pena L, Fumagalli D, de Azambuja E, de Braud F, Daidone MG. BIG 1-06 NeoALTTO SABCS2016, 2016; P3-02 SABC2016
2016 RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial Fumagalli D, Venet D, Ignatiadis M1, Azim HA Jr, Maetens M, Roth F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Pea L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C BIG 1-06 NeoALTTO JAMA Oncol. 2016 Sep 29. doi: 10.1001/jamaoncol.2016.3824. JAMA Oncology
2016 Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial M. Ignatiadis, B. Rack, F. Rothe, S. Riethdorf, C. Decraene, H. Bonnefoi, C. Dittrich, C. Messina, M. Beauvois, E. Trapp, T. Goulioti, K. Tryfonidis, K. Pantel, M. Repollet, W. Janni, M. Piccart, C. Sotiriou, S. Litiere, J.-Y. Pierga BIG 1-12 Treat CTC European Journal of Cancer 63 (2016) 97e104 European Journal of Cancer
2016 Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17. Goodwin RA, Jamal R, Booth CM, Goss PE, Eisenhauer EA, Tu D, Shepherd LE. BIG 1-97 MA.17 Eur J Cancer. 2016 May;58:97-103. doi: 10.1016/j.ejca.2016.01.014. Epub 2016 Mar 14. European Journal of Cancer
2016 New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17. Liedke PE, Tu D, Shepherd L, Chavarri-Guerra Y, Pritchard KI, Stearns V, Goss PE. BIG 1-97 MA.17 Breast. 2016 Jun;27:99-104. doi: 10.1016/j.breast.2016.02.010. Epub 2016 Apr 5. Breast
2016 Treatment adherence in the BIG 1-98 trial of tamoxifen, letrozole alone and in sequence. Chirgwin J,Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, Lng I, Colleoni M, Thrlimann B for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. BIG 1-98 J Clin Oncol 34:2452-2459, 2016. Journal of Clinical Oncology
2016 Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, Lng I, Colleoni M, Thrlimann B. BIG 1-98 J Clin Oncol. 2016 May 23. pii: JCO638619. [Epub ahead of print] Journal of Clinical Oncology
2016 The genomic grade assay compared with Ki67 to determine risk of distant breast cancer recurrence. Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Roth F, Laos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C. BIG 1-98 JAMA Oncol 2:217-224, 2016. JAMA Oncology
2016 Evaluating markers for guiding treatment. Baker SG, Bonetti M. BIG 1-98 J Natl Cancer Inst (2016) 108 (9): djw101 doi:10.1093/jnci/djw101 First published online May 18, 2016 (6 pages). Journal of the National Cancer Institute
2016 Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study. Loi S, Asher R, Lee CK, Luen S, Savas P, Kammler R, Dell'Orto P, Blasi OM, Demanse D, JeBailley L, Dolan S, Hackl W, Thuerlimann B, Viale G, Regan M, Colleoni MA BIG 1-98 SABCS2016, 2016; S1-10 SABC2016
2016 Twelve-month estrogen levels in premenopausal women with hormone-receptor positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the SOFT trial: the SOFT-EST substudy Bellet M, Gray KP, Francis PA, Lang I, Ciruelos E, Lluch A, Climent MA, Cataln G, Avella Mestre A, Bohn U, Gonzlez-Martin A, Costa RF, Cataln R, Azaro A, Rajasekaran A, Morales J, Vzquez J, Fleming GF, Price KN, Regan MM, SOFT-EST Investigators, SOLTI, and International Breast Cancer Study Group. BIG 2-02 SOFT; BIG 3-02 TEXT J Clin Oncol 34:1584-1593, 2016. (IBCSG 24-02) Journal of Clinical Oncology
2016 Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Johansson H, Gray KP,Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA; the TEXT principal investigators. BIG 2-02 SOFT; BIG 3-02 TEXT Breast Cancer Res 18:110, 2016. (IBCSG 25-02) (Journal impact factor 5.211). Breast Cancer Research
2016 Are SOFT and TEXT results practice changing and how? Pagani O, Regan MM, Francis PA. BIG 2-02 SOFT; BIG 3-02 TEXT Breast 27:122-125, 2016. (IBCSG 24-02 and 25-02 commentary) Breast
2016 Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial. Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Kerbrat P, Perell A, Neven P, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates AS, Goldhirsch A, Price KN, Gelber RD, Regan MM, Fleming GF. BIG 2-02 SOFT; BIG 3-02 TEXT J Clin Oncol 34:1601-1610, 2016. (IBCSG 24-02) Journal of Clinical Oncology
2016 Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Feng Y, Price KN, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Ahles T, Fleming GF, Bernhard J. BIG 2-02 SOFT; BIG 3-02 TEXT Br J Cancer 114:956-964, 2016. (IBCSG 24-02) British Journal of Cancer
2016 Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Lng I, Gmez HL, Tondini C, Pinotti G, Price KN, Coates AS, Goldhirsch A, Gelber RD. BIG 2-02 SOFT; BIG 3-02 TEXT J Clin Oncol. 2016 Apr 4. pii: JCO643171. Journal of Clinical Oncology
2016 Lapatinib-Related Rash and Breast Cancer Outcome in theALTTOPhase III Randomized Trial. Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr. BIG 2-06 ALTTO J Natl Cancer Inst. 2016 Apr 20;108(8). pii: djw037. doi: 10.1093/jnci/djw037. Print 2016 Aug. J Natl Cancer Inst.
2016 Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial. Gringas I, Holmes EM, De Azambuja E, Nguyen DHA, Izquierdo MA, Zujewski JA, Inbar MJ, Naume B, Tomasello G, Gnant M, Moreno-Aspitia A, Piccart-Gebhart MJ, Azim HA. BIG 2-06 ALTTO Journal of Clinical Oncology. 2016; 34 , (supp; abstr 604) Journal of Clinical Oncology
2016 Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04MINDACTtrial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance. Viale G, Slaets L, de Snoo FA, Bogaerts J, Russo L, Van't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Dell'Orto P, Glas AM, Cardoso F. BIG 3-04 MINDACT Breast Cancer Res Treat. 2016 Feb;155(3):463-9. doi: 10.1007/s10549-016-3690-6. Epub 2016 Jan 28. Breast Cancer Research and Treatment
2016 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators BIG 3-04 MINDACT N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253. New England Journal of Medicine
2016 LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer. Saura C, De Azambuja E, Oliveira M, Dubsky PC, Zardavas D, Fesl C, Bardia A, Soberino J, Fornier MN, Boer K, Ng V, Fredrickson JO, Stout T, Singel S, Hsu JY, PIccart-Gebhart MJ, Baselga J, Gnant M. BIG 3-13 LORELEI Journal of Clinical Oncology. 2016; 34 , (suppl; abstr TPS613) Journal of Clinical Oncology
2016 Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators. BIG 5-02 IBIS-II Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11. Lancet
2016 Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. Fadoukhair Z, Zardavas D, Chad MA, Goulioti T, Aftimos P, Piccart M. General Oncogene. 2016 Apr 7;35(14):1743-9. doi: 10.1038/onc.2015.249. Epub 2015 Jun 29. Oncogene
2016 Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr BIG 2-06 ALTTO J Natl Cancer Inst. 2016 Apr 20; doi: 10.1093/jnci/djw037 Journal of the National Cancer Institute
2015 Pregnancy after breast cancer: Are young patients willing to participate in clinical studies? Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair OM, Pistilli B, Warner E, Saloustros E, Pere